A study in humans with coronary artery disease identified the mir-596 as a biomarker for recurrent myocardial infarction risk, where it was downregulated in whole blood of patients with recurrent MI compared to those without, with this differential expression remaining significant after false discovery rate correction (FDR <0.1) [Onuoha et al. DOI:10.1111/cts.13307]. The investigation found no significant differential expression for the mir-596 in plasma samples from the same cohort, indicating whole blood as the preferred sample source for this biomarker in the context of cardiovascular risk assessment.